|
Product Details:
Payment & Shipping Terms:
|
Name: | Everolimus | Appearance: | White Powder |
---|---|---|---|
CAS: | 159351-69-6 | Package: | Aluminum Foil Bag |
Production Capacity: | 500 Kilogram/month | Storage: | Kept In A Cool,dry And Ventilated Place |
Purity: | 99% | MF: | C53H83NO14 |
High Light: | Everolimus Research Chemical Powder,CAS 159351-69-6 Research Chemical Powder,C53H83NO14 Research Chemical Powder |
Everolimus Powder Anti-Cancer Drug CAS 159351-69-6 Everolimus reliable supplier
Product name | Everolimus |
CAS No. | 159351-69-6 |
Molecular formula | C53H83NO14 |
Molecular weight | 958.22 |
Purity | 99% |
Appearance | White or almost white powder |
Package | Aluminum Bag;Drums |
Shelf life | 2 years |
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Contact Person: July
Tel: 25838890